Abstract
Ticlopidine is an antiplatelet agent that is used to reduce the occurrence of atherothrombotic arterial events. There have been major multicentre placebo-controlled trials evaluating its use in stroke, peripheral arterial disease and unstable angina. In rare cases, adverse haematological effects have been seen with ticlopidine.
Ticlopidine has been associated with neutropenia in some of the major trials and in subsequent case reports it has been associated with aplastic anaemia, thrombocytopenia and thrombotic thrombocytopenic purpura, which have been fatal in some instances. Ticlopidine should be used only in patients with an established indication for its use. Patients should be educated about the potential adverse effects and complications associated with ticlopidine, including possible death. Finally, there should be careful attention to haematological monitoring to screen for and promptly detect any adverse effects.
Similar content being viewed by others
References
Gent M, Blakeley JA, Easton JD, and the CATS Group. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20
Hass WK, Easton JD, Adams HP, et al. for the Ticlopidine Aspirin Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501–7
Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301–8
Balsano F, Rizzon P, Violi F, et al. and the STAI group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17–26
Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulation therapy after the placement of coronary-artery-stents. N Engl J Med 1996; 334: 1084–9
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Becquemin J-P, for the Etude de la Ticlopidine Aprés Pontage Femero-Poplité and the Association Universitaire de Recherche en Chirugie. Effect of ticlopidine on long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726–31
Saltiel E, Ward A: Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–62
Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 813-36
Defreyn G, Bernat A, Delebassee D, et al. Pharmacology of ticlopidine: a review. Semin Thromb Hem 1989; 15: 159–66
Shah J, Teitelbaum P, Moloby B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991; 32: 761–4
Barnett HJM, Eliasziw M, Meldrum HE. Prevention of ischemic stroke [letter]. N Engl J Med 1995; 333: 460
Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [letter]. JAMA 1996; 276: 952
National Disease and Therapeutic Index. Plymouth Meeting PA: IMS America, 1992–1995
Quaglino D, Venturoni L, Cretara G, et al. Reversible bone marrow suppression primarily involving granulopoiesis following the use of ticlopidine. Haematologica 1982; 67: 940–1
Resegotti L, Pistone MA, Testa D, et al. Bone marrow culture in patients receiving ticlopidine treatment. Nouv Rev Fr Hematol 1985; 27: 19–22
Abou-Khalil WH, Lim LO, Yunnis AA, et al. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism, oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984; 33: 3893–8
Haynes RB, Sandler RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152: 1376–80
Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349: 474–5
Ono K, Kurohara K, Yoshihara M, et al. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematology 1991; 37: 239–42
Elias M, Reichman N, Flatau E. Bone marrow aplasia associated with ticlopidine therapy [letter]. Am J Hematol 1993; 44: 289–91
Farver DK, Hansen LA. Delayed neutropenia with ticlopidine. Ann Pharmacother 1994; 28: 1344–6
Gelatko SM, Melbourne KM, Mikolich DJ. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia. Ann Pharmacother 1996; 30: 246–8
Johanning RJ, Tschida SJ. Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis [letter]. Ann Pharmacother 1996; 30: 1201
Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236–7
Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, et al. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994; 91: 106–7
Gamier G, Taillan B, Pesce A, et al. Ticlopidine and severe aplastic anemia [letter]. Br J Haematology 1992; 81: 459–60
Troussard X, Mayo P, Mosquet B, et al. Ticlopidine and severe aplastic anemia [letter]. Br J Haematol 1992; 82: 779–80
Khelif A, Assouline D, French M, et al. Ticlopidine and aplastic anaemia [letter]. Br J Haematol 1993; 83: 678–81
Martin-Nunez G, Fdex-Soria RR, Sanchez-Gil F, et al. Aplastic anemia and ticlopidine [letter]. Br J Haematol 1991; 85: 633–40
Lesesve J-F, Callat M-P, Lenormand B, et al. Hematological toxicity of ticlopidine [letter]. Am JHematol 1994; 47: 149–50
Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28: 1169–71
Rodriguez JN, Fernandez-Jurado A, Dieguez JC, et al. Ticlopidine and severe aplastic anemia [letter]. Am J Hematol 1994; 47: 332
Arribalzaga K, Garcia-Suärez, Lopez-Rubio M, et al. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia [letter]. Am J Hematol 1995; 50: 313–20
Dunn P. Aplastic anemia with ticlopidine therapy in two Chinese patients [letter]. Ann Pharmacother 1996; 30: 547
Shapiro CM, Walk D. Aplastic anemia associated with ticlopidine [letter]. Neurology 1996; 47: 300
Yunis AA, Arimura GK, Lo L. Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CGU-GM) growth. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 1984; 15: 136–47
Takishita S, Kawazoe N, Yoshida T, et al. Ticlopidine and thrombocytopenia [letter]. N Engl J Med 1990; 323: 1487
Capra R, Marciano N, Fieni F, et al. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report. Acta Neurol Belg 1992; 92: 83–7
Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. Am J Hematol 1997; 54: 175–6
Falezza G, Girelli D, Olivieri O, et al. Thrombotic thrombocytopenic purpura developed during ticlopidine therapy [letter]. Haematologica 1992; 77: 525
Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993; 27: 1060–1
Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774–6
Ellie E, Durrieu C, Besse P, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke 1992; 23: 922–3
Piscotto P. Treatment of thrombocytopenic purpura: evaluation of plasma exchange and review of the literature. Vox Sang 1983; 45: 185–96
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Love, B.B., Biller, J. & Gent, M. Adverse Haematological Effects of Ticlopidine. Drug-Safety 19, 89–98 (1998). https://doi.org/10.2165/00002018-199819020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199819020-00002